U.S. markets close in 2 minutes
  • S&P 500

    4,472.44
    +34.18 (+0.77%)
     
  • Dow 30

    35,307.55
    +394.99 (+1.13%)
     
  • Nasdaq

    14,899.03
    +75.60 (+0.51%)
     
  • Russell 2000

    2,276.30
    +2.12 (+0.09%)
     
  • Crude Oil

    82.24
    +0.93 (+1.14%)
     
  • Gold

    1,768.90
    -29.00 (-1.61%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1608
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • GBP/USD

    1.3747
    +0.0070 (+0.51%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    61,414.48
    +3,645.11 (+6.31%)
     
  • CMC Crypto 200

    1,445.86
    +39.12 (+2.78%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Baudax Bio to Participate at the Oppenheimer 31st Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will participate in a fireside chat at the virtual Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 9:20 a.m. ET.

A live webcast of the fireside chat will be available on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be made available for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit www.baudaxbio.com.


CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com